Prognostic implications and therapeutic response in GNAS-mutated colorectal adenocarcinoma: A retrospective cohort analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.244
Abstract: 244 Background: GNAS, a key regulator of the G-protein signaling pathway, is frequently mutated in colorectal adenocarcinomas and other malignancies. Despite its role in tumorigenesis, GNAS mutations remain understudied, with no established targeted therapies. Exploring… read more here.
Keywords: gnas mutations; disease; response; therapeutic response ... See more keywords
MicroRNA Expression in KRAS- and BRAF-mutated Colorectal Cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Anticancer research"
DOI: 10.21873/anticanres.12272
Abstract: BACKGROUND/AIM KRAS and BRAF are two genes commonly mutated in colorectal cancer (CRC). Even though BRAF is a downstream target of KRAS in the MAPK signalling pathway, KRAS- and BRAF-mutated CRCs are found to display… read more here.
Keywords: kras braf; mir; braf mutated; mutated colorectal ... See more keywords
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15082375
Abstract: Simple Summary More than a third of all colorectal cancers have a KRAS mutation. The complex biology of these cancers has challenged the development of direct targeting inhibitors. Substantial leaps have been made in recent… read more here.
Keywords: colorectal cancers; cancers therapeutic; development; mutated colorectal ... See more keywords